GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perseus Proteomics Inc (TSE:4882) » Definitions » LT-Debt-to-Total-Asset

Perseus Proteomics (TSE:4882) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Perseus Proteomics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Perseus Proteomics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Perseus Proteomics's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).


Perseus Proteomics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Perseus Proteomics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perseus Proteomics LT-Debt-to-Total-Asset Chart

Perseus Proteomics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial - - - - -

Perseus Proteomics Quarterly Data
Mar18 Mar19 Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Perseus Proteomics LT-Debt-to-Total-Asset Calculation

Perseus Proteomics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )/Total Assets (A: Mar. 2023 )
=0/2566.65
=0.00

Perseus Proteomics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0/1796.664
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perseus Proteomics  (TSE:4882) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Perseus Proteomics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Perseus Proteomics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Perseus Proteomics (TSE:4882) Business Description

Traded in Other Exchanges
N/A
Address
4-7-6, Komaba, Tokyo Park Building, Meguro-ku, Tokyo, JPN, 153-0041
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody based therapeutics and diagnostics drugs to cure against cancer and other diseases.

Perseus Proteomics (TSE:4882) Headlines

No Headlines